Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Single- Versus Two-Fraction HDR Brachytherapy Boost for Prostate Cancer: Long-Term Oncologic and Toxicity Outcomes.

Created on 19 Nov 2026

Authors

Alai Goñi, Macarena Sevilla, Mikel Larruskain, Mikel Eguiguren, Ainhoa Perez, Eva Sáenz de Urturi, Usoa Iceta, Daniel Alberto Roura, Maider Alberich, Julian Minguez, Jose María Urraca, Arrate Querejeta

Published in

Practical radiation oncology. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

High-dose-rate (HDR) brachytherapy boost with external beam radiotherapy (EBRT) is an established dose-escalation strategy for high-risk prostate cancer, but the optimal number of HDR fractions is unclear. We compared oncological outcomes and toxicity between single- and two-fraction HDR boost.
Retrospective cohort of 378 patients with localized prostate cancer treated as high risk by institutional criteria (D'Amico-based; regrouped by NCCN) in 2004-2016 with EBRT (46 Gy) and a CT-guided HDR boost. Before November 2009, patients received EBRT followed by two HDR fractions of 9-10 Gy 8 hours apart (n=205); from November 2009, a single 15 Gy fraction preceded EBRT (n=173). Biochemical recurrence-free (BRFS), metastasis-free, cancer-specific (CSFS), and grade ≥3 genitourinary (GUTFS) and gastrointestinal toxicity-free survival were estimated with Kaplan-Meier and compared with the log-rank test; Cox models were fitted.
Median follow-up was 130.1 months (IQR 94-158). Single-fraction patients more often had cT3 disease (72.3% vs. 43.4%) and NCCN high or very high risk (84.4% vs. 67.8%). At 10 years, BRFS, MFS, and CSFS were 81.4%, 91.5%, and 95.4%, without significant differences between one and two fractions (BRFS 79.6% vs. 82.6%, p=0.784; CSFS 95.3% vs. 95.4%, p=0.992). Crude grade ≥3 GU toxicity was higher with two fractions (22.9% vs. 10.4%, p=0.002); 10-year GUTFS was 82.2% vs. 89.7% (p=0.076). PSA and Gleason score >7 independently predicted CSFS and BRFS.
In this non-randomized comparison of consecutive protocols, one and two HDR boost fractions showed no significant difference in long-term oncological control. The confidence intervals were wide, and equivalence was not tested. Two fractions had more grade ≥3 GU toxicity, which cannot be separated from treatment era, EBRT sequence, and follow-up. A single 15 Gy fraction appears adequate as a boost combined with EBRT. It does not apply to HDR monotherapy. Prospective confirmation is needed.

PMID:
43051583
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement